These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 12781043)
1. Effect of progesterone combined with chemotherapy on epithelial ovarian cancer. Chen X; Feng Y Chin Med J (Engl); 2003 Mar; 116(3):388-91. PubMed ID: 12781043 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC; Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296 [TBL] [Abstract][Full Text] [Related]
3. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459 [TBL] [Abstract][Full Text] [Related]
4. [Analysis of risk factors for epithelial ovarian cancer recurrence]. Liu S; Liu JH; Huang H; Peng XP; Wang YM Ai Zheng; 2003 Nov; 22(11):1197-200. PubMed ID: 14613652 [TBL] [Abstract][Full Text] [Related]
5. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Rubin SC; Wong GY; Curtin JP; Barakat RR; Hakes TB; Hoskins WJ Obstet Gynecol; 1993 Jul; 82(1):143-7. PubMed ID: 8515915 [TBL] [Abstract][Full Text] [Related]
6. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique). Morice P; Leblanc E; Rey A; Baron M; Querleu D; Blanchot J; Duvillard P; Lhommé C; Castaigne D; Classe JM; Bonnier P; Hum Reprod; 2005 May; 20(5):1379-85. PubMed ID: 15817592 [TBL] [Abstract][Full Text] [Related]
7. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer]. Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495 [TBL] [Abstract][Full Text] [Related]
8. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study. Safra T; Kovner F; Barak N; Inbar MJ; Ron IG Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747 [TBL] [Abstract][Full Text] [Related]
10. Advances in the management of epithelial ovarian cancer. Berkenblit A; Cannistra SA J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567 [TBL] [Abstract][Full Text] [Related]
11. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534 [TBL] [Abstract][Full Text] [Related]
12. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F Oncology; 2009; 76(1):49-54. PubMed ID: 19039248 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Liu EL; Mi RR Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381 [TBL] [Abstract][Full Text] [Related]
14. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P; J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064 [TBL] [Abstract][Full Text] [Related]
16. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314 [TBL] [Abstract][Full Text] [Related]
17. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408 [TBL] [Abstract][Full Text] [Related]
18. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698 [TBL] [Abstract][Full Text] [Related]